LegoChem Biosciences Enters into a Collaboration Agreement with Janssen Biotech to Develop and Commercialize LCB84 Trop2-Targeted ADC
Shots:
- LegoChem signs a license agreement with Janssen Biotech to develop and commercialize LCB82 across the globe. Both companies are expected to collaborate during the ongoing P-I/II trial (across the US) following which Janssen will be held responsible for further development & commercialization after option exercise
- As per the terms of the agreement, LegoChem will receive an aggregate of $1.7B which includes an up front payment of $100M, an option exercise payment of $200M along with potential development, regulatory & commercial milestone payments, plus tiered royalties
- LCB84 is a Trop2-directed ADC developed through LegoChem’s ADC platform technology & Trop2 Ab licensed from Mediterranea Theranostic
Ref: LegoChem | Image: LegoChem
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
